ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis

ClinicalTrials.gov ID: NCT05083182

Public ClinicalTrials.gov record NCT05083182. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 5:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Multicenter, Open-label Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of Subcutaneously Administered Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis (PSUMMIT-Jr)

Study identification

NCT ID
NCT05083182
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Janssen Research & Development, LLC
Industry
Enrollment
50 participants

Conditions and interventions

Interventions

  • Guselkumab Drug
  • Ustekinumab Drug

Drug

Eligibility (public fields only)

Age range
5 Years to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 29, 2022
Primary completion
Jan 11, 2026
Completion
Dec 4, 2026
Last update posted
Apr 12, 2026

2022 – 2026

United States locations

U.S. sites
9
U.S. states
7
U.S. cities
8
Facility City State ZIP Site status
Childrens Hospital Los Angeles Los Angeles California 90027
UCLA Los Angeles California 90095-3075
Harvard Medical School - Boston Children's Hospital Boston Massachusetts 02215-5450
Northwell Health New York New York 11040
Montefiore Medical Center The Bronx New York 10467-2403
University of North Carolina Chapel Hill North Carolina 27514
Cincinnati Children's Hospital Medical Center Cincinnati Ohio 45229
Legacy Emanuel Medical Center Portland Oregon 97227
University of Utah Salt Lake City Utah 84132

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05083182, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 12, 2026 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05083182 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →